{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:54Z","timestamp":1793155794256,"version":"4.5.0"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ixekizumab proved to be effective and safe for psoriasis treatment in several randomized clinical trials and real\u2010life studies. Nevertheless, long\u2010term real\u2010world experiences are still lacking, with little data up to 4\u2009years of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse survival, effectiveness and safety of ixekizumab in a real\u2010life cohort of patients affected by moderate\u2010to\u2010severe psoriasis or psoriatic arthritis up to 260\u2009weeks (5\u2009years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included all patients treated with ixekizumab from December 2017 to March 2021. Drug survival (DS) was analysed in patients at risk for up to 5\u2009years. Cox analysis was adopted to evaluate possible predictive factors of discontinuation. Psoriasis Area Severity Index (meanPASI and PASI100, 90, and \u22643) was used as outcomes of effectiveness on observed patients at 16, 52, 104, 156, 208 and 260\u2009weeks. Logistic regression was performed to identify possible predictive factors of response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      DS was 65.5% at 260\u2009weeks, with being a super\u2010responder patient (achievement of PASI100 at 16\u2009weeks and maintained at 28\u2009weeks) correlated with less risk of discontinuation. PASI100, 90 and \u22643 was achieved by 54.1%, 60.5% and 73% of observed patients, respectively, at 16\u2009weeks, and by 59.1%, 81.8% and 95.5%, respectively, at 260\u2009weeks. High mean BMI was the only factor strongly associated with less achievement of the outcomes at the earlier time points: PASI100 at 16\u2009weeks (OR 0.93, CI 0.87\u20130.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014) and at 104\u2009weeks (OR 0.91, CI 0.84\u20130.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), PASI90 achievement at 16\u2009weeks (OR 0.94, CI 0.88\u20130.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028) and 104\u2009weeks (OR 0.91, CI 0.83\u20130.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027), and PASI \u22643 (OR 0.86, CI 0.76\u20130.97,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018) at 104\u2009weeks. No severe adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ixekizumab showed high effectiveness and safety for up to 5\u2009years, with survival of 2\/3 of treated patients. Rapid response to treatment is predictive of long\u2010term response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19682","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T13:08:05Z","timestamp":1703596085000},"page":"568-575","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Drug survival, effectiveness and safety of ixekizumab for moderate\u2010to\u2010severe psoriasis up to 5\u2009years"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"L.","family":"Mastorino","sequence":"first","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9856-4450","authenticated-orcid":false,"given":"L.","family":"Burzi","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rosset","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Giunipero\u00a0di\u00a0Corteranzo","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Leo","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Verrone","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Stroppiana","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"S.","family":"Ribero","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"P.","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14822"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.12.001"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.156084"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1961998"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14874"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17766"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041662"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2193288"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.022"},{"key":"e_1_2_11_11_1","unstructured":"Taltz | European Medicines Agency \u2010 European Union.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz(last consultation 30\/08\/2023)."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14731"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010020\u201000475\u20108"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.031"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6101"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2082354"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16737"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000867\u2010y"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56110584"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010022\u201000722\u2010y"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T06:39:03Z","timestamp":1708929543000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/jdv.19682"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19682","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"2023-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}